Italia markets closed

Alvotech (ALVOW)

NasdaqGM - NasdaqGM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,1000-0,0800 (-2,52%)
Alla chiusura: 04:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,1800
Aperto3,1000
Denaro0,0000 x 0
Domanda0,0000 x 0
Min-Max giorno3,1000 - 3,1000
Intervallo di 52 settimane3,1000 - 3,1000
Volume13
Media VolumeN/D
CapitalizzazioneN/D
Beta (mensile su 5 anni)-0,05
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT04, a biosimilar candidate to Stelara® (ustekinumab). As expected, the CRL noted that certain deficiencies, which were conveyed following the FDA’s inspection of the company’s Reykjavik fac

  • GlobeNewswire

    Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland

    Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price. Islandsbanki will post bids and offers on the exchange amounting to at least ISK 8 million at market value at any given time at a price determined by Islandsbanki, wh

  • GlobeNewswire

    Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

    REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company, today announced that they have entered into an exclusive licensing agreement for AVT23 (also called ADL018), a proposed biosimilar to Xolair® (omalizumab), which is currently in clinical developm